Zobrazeno 1 - 5
of 5
pro vyhledávání: '"S. M. Tolaney"'
Autor:
Z, Bakouny, C, Labaki, S, Bhalla, A L, Schmidt, J A, Steinharter, J, Cocco, D A, Tremblay, M M, Awad, A, Kessler, R I, Haddad, M, Evans, F, Busser, M, Wotman, C R, Curran, B S, Zimmerman, G, Bouchard, T, Jun, P V, Nuzzo, Q, Qin, L, Hirsch, J, Feld, K M, Kelleher, D, Seidman, H, Huang, H M, Anderson-Keightly, T, El Zarif, S Abou, Alaiwi, C, Champagne, T D, Rosenbloom, P S, Stewart, B E, Johnson, Q, Trinh, S M, Tolaney, M D, Galsky, T K, Choueiri, D B, Doroshow
Publikováno v:
Annals of Oncology. 33:836-844
COVID-19 disproportionately impacted patients with cancer as a result of direct infection, and delays in diagnosis and therapy. Oncological clinical trials are resource-intensive endeavors that could be particularly susceptible to disruption by the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1b4282fde15ec83b80eb63c3f9addfa
https://doi.org/10.1016/j.annonc.2022.04.071
https://doi.org/10.1016/j.annonc.2022.04.071
Autor:
P, Tarantino, H J, Burstein, N U, Lin, I E, Krop, E P, Winer, S J, Schnitt, E P, Hamilton, S A, Hurvitz, H S, Rugo, G, Curigliano, S M, Tolaney
Publikováno v:
Annals of Oncology. 33:234-238
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::729b79003b8702847496928fa1713e91
https://doi.org/10.1016/j.annonc.2021.12.004
https://doi.org/10.1016/j.annonc.2021.12.004
Autor:
A. S. Feils, A. K. Erbe, J. Birstler, K. Kim, U. Hoch, S. L. Currie, T. Nguyen, D. Yu, A. O. Siefker-Radtke, N. Tannir, S. M. Tolaney, A. Diab, P. M. Sondel
Publikováno v:
Cancer Immunology, Immunotherapy.
Bempegaldesleukin (BEMPEG), a CD122-preferential IL2 pathway agonist, has been shown to induce proliferation and activation of NK cells. NK activation is dependent on the balance of inhibitory and excitatory signals transmitted by NK receptors, inclu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::219f2e38434efb5aa9923915f90abcb4
https://doi.org/10.1007/s00262-023-03383-w
https://doi.org/10.1007/s00262-023-03383-w
Publikováno v:
Clinical and Translational Oncology. 23:1979-1994
The year 2019 witnessed the first approval of an immune checkpoint inhibitor (ICI) for the management of triple negative breast cancers (TNBC) that are metastatic and programmed death ligand (PD)-L1 positive. Extensive research has focused on testing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::184e4295b96a80482043a639123ddac2
https://doi.org/10.1007/s12094-021-02613-w
https://doi.org/10.1007/s12094-021-02613-w
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 23(10)
The year 2019 witnessed the first approval of an immune checkpoint inhibitor (ICI) for the management of triple negative breast cancers (TNBC) that are metastatic and programmed death ligand (PD)-L1 positive. Extensive research has focused on testing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c329df8177edf1504505ae024c0ae346
https://pubmed.ncbi.nlm.nih.gov/33871826
https://pubmed.ncbi.nlm.nih.gov/33871826